Search

Your search keyword '"Afzali, Anita"' showing total 12 results
Start Over Author "Afzali, Anita" Publication Year Range This year
12 results on '"Afzali, Anita"'

1. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Author

Oliinyk, Oleksandr, Bilianskyi, Leonid, Gniady-Jastrzebska, Jadwiga, Petryka, Robert, Arlukowicz, Tomasz, Gietka, Piotr, Zmudzinski, Marcin, Mumtaz, Syed, Wolf, Douglas, Wojcik, Katarzyna, Duvall, George, Augustyn, Monika, Filip, Rafal, Tarabar, Dino, Tkachev, Alexander, Seidler, Ursula, Zittan, Eran, Pokrotnieks, Juris, Shchukina, Oksana, Machavariani, Andro, Loy, Laura, Abu-farsakh, Niazy, Marina, Pesegova, Sreckovic, Slobodan, Laclav, Martin, Wei, Shu-Chen, Suiter, Daniel, Borsuk, Aleksey, Hebuterne, Xavier, Buning, Carsten, Lahat-Zok, Adi, Danilkiewicz, Wit, Frysna, Bernadetta, Jovicic, Ivana, Datsenko, Olena, Guram, Maninder, Jain, Animesh, Rashid, Zahid, Heeren, Sonja, Shulga, Natallia, Timkin, Ivan, Gornjakovic, Srdjan, Lukas, Milan, Altwegg, Romain, Desjeux, Ariadne, Reimund, Jean-Marie, Giorgadze, Manana, Jochum, Christoph, Ito, Hiroaki, Nakai, Katsuhiko, Takagi, Tomohisa, Zaha, Osamu, Choi, Changhwan, Kim, Taeoh, Lee, Jonghun, Stundiene, Ieva, Hilmi, Ida Normiha, Hj Md Said, Rosaida, Leszczyszyn, Jaroslaw, Abdulganieva, Diana, Fominykh, Yulia, Maksyashina, Svetlana, Balaz, Jozef, Van Domselaar, Manuel, Kav, Taylan, Dennis, Patrick, Henry, Patricia, Holmes, Robert, Johnson, Christopher, McBride, Matthew, Sarles, Harry, Moore, Gregory, Yakubtsevich, Ruslan, Muls, Vinciane, Trbojevic, Stevan, Afif, Waqqas, Bernstein, Charles, Klarin, Ivo, Serclova, Zuzana, Volfova, Miroslava, Desreumaux, Pierre, Gilletta de Saint Joseph, Cyrielle, Roblin, Xavier, Vuitton, Lucine, Chelidze, Kakhaber, Kuehbacher, Tanja, Koutroubakis, Ioannis, Cicala, Michele, Fries, Walter, Gasbarrini, Antonio, Aoyama, Nobuo, Hayashi, Yoshito, Hirai, Fumihito, Horiki, Norkiyuki, Hoshi, Namiko, Inaba, Tomoki, Hiroyasu, Ishida, Maemoto, Atsuo, Matsumoto, Takayuki, Matsushima, Kayoko, Motoya, Satoshi, Taruishi, Masaki, Rashid, Mohammed, Chun, Jaeyoung, Kim, Young-Ho, Park, Dong Il, Sharara, Ala, Jonaitis, Laimas, Deriban, Gjorgi, Brooker, James, Gawdis-Wojnarska, Beata, Wozniak-Stolarska, Barbara, Andreev, Pavel, Simanenkov, Vladimir, Trofimov, Vasiliy, Jovanovic, Igor, Zdravkovic, Natasa, Aldeguer i Mante, Xavier, Hernandez Ramirez, Vicent, Akpinar, Hale, Celebi, Gurkan, Hamzaoglu, Hulya, Fernandez, Juan, Kamath, Jayaprakash, Palekar, Nicole, Pruthi, Jatinder S., Rausher, David, Ritter, Timothy, Danese, Silvio, Panaccione, Remo, Feagan, Brian G, Afzali, Anita, Rubin, David T, Sands, Bruce E, Reinisch, Walter, Panés, Julián, Sahoo, Aparna, Terry, Natalie A, Chan, Daphne, Han, Chenglong, Frustaci, Mary Ellen, Yang, Zijiang, Sandborn, William J, Hisamatsu, Tadakazu, Andrews, Jane M, and D'Haens, Geert R

Published
2024
Full Text
View/download PDF

3. Surgery for Crohn’s Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts

Author

Wolf, Douglas C., Hron, Bridget, Hanson, John S., Mohanty, Sanjib P., Fogel, Ronald P., Levy, L. Campbell, Iskandar, Heba N., Fischer, Monika, Cohen, Benjamin, Swaminath, Arun, Kane, Sunanda, McCabe, Robert P., Jr., Yen, Eugene F., Hanauer, Stephen B., Hudesman, David P., Afzali, Anita, Kelly, Colleen, Weber, John R., Mahadevan, Uma, Herfarth, Hans, Katz, Jeffery, Taleban, Sasha, Rubin, David T., Yachyshyn, Bruce, Reynolds, Gorman J., Gerich, Mark, Dryden, Gerald W., Quezada, Sandra, Higgins, Peter D.R., Shmidt, Eugenia, Lewis, James D., Schwartz, Marc B., Flynn, Ann D., Saha, Sumona, Horst, Sara N., Chiorean, Michael, Green, Patrick D., Scherl, Ellen J., Sandler, Robert, Brotherton, Carol, Albenberg, Lindsey, Valentine, John F., Suskind, David, Meyer, Andrea, Compher, Charlene W., Bewtra, Meenakshi, Kaur, Manreet, Dassopoulos, Themistocles, Snapper, Scott B., Korzenik, Joshua R., Bohm, Matthew, Raffals, Laura, Beniwal-Patel, Poonam, Hudesman, David, Russ, Kirk, Brook, Loren, Pekow, Joel, Cross, Raymond, Wong, Uni, Bishu, Shrinivas, Duerr, Richard, Caldera, Freddy, Scoville, Elizabeth, Deepak, Parakkal, Ciorba, Matthew, Daniel, Scott G., Li, Hongzhe, Hao, Fuhua, Patterson, Andrew D., Hecht, Aaron L., Brensinger, Colleen M., Wu, Gary D., and Bittinger, Kyle

Published
2024
Full Text
View/download PDF

5. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 G 3 PHASE 3 STUDIES

Author

Panaccione, Remo, primary, Danese, Silvio, additional, Feagan, Brian G., additional, D’Haens, Geert, additional, Afzali, Anita, additional, Reinisch, Walter, additional, Panés, Julián, additional, Rubin, David T., additional, Andrews, Jane M., additional, Hisamatsu, Tadakazu, additional, Terry, Natalie A., additional, Salese, Leonardo, additional, Van Rampelbergh, Rian, additional, Frustaci, Mary Ellen S., additional, Yang, Zijiang, additional, Johanns, Jewel, additional, Wan, Kitty Y., additional, Yee, Jacqueline, additional, and Sands, Bruce E., additional

Published
2024
Full Text
View/download PDF

6. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts

Author

Lewis, James D., primary, Daniel, Scott G., additional, Li, Hongzhe, additional, Hao, Fuhua, additional, Patterson, Andrew D., additional, Hecht, Aaron, additional, Brensinger, Colleen M., additional, Wu, Gary D., additional, Bittinger, Kyle, additional, Wolf, Douglas C., additional, Hron, Bridget, additional, Hanson, John S., additional, Mohanty, Sanjib P., additional, Fogel, Ronald P., additional, Levy, L. Campbell, additional, Iskandar, Heba N., additional, Fischer, Monika, additional, Cohen, Benjamin, additional, Swaminath, Arun, additional, Kane, Sunanda, additional, McCabe, Robert P., additional, Yen, Eugene F., additional, Hanauer, Stephen B., additional, Hudesman, David P., additional, Afzali, Anita, additional, Kelly, Colleen, additional, Weber, John R., additional, Mahadevan, Uma, additional, Herfarth, Hans, additional, Katz, Jeffery, additional, Taleban, Sasha, additional, Rubin, David T., additional, Yachyshyn, Bruce, additional, Reynolds, Gorman J., additional, Gerich, Mark, additional, Dryden, Gerald W., additional, Quezada, Sandra, additional, Higgins, Peter D.R., additional, Shmidt, Eugenia, additional, Lewis, James D., additional, Schwartz, Marc B., additional, Flynn, Ann D., additional, Saha, Sumona, additional, Horst, Sara N., additional, Chiorean, Michael, additional, Green, Patrick D., additional, Scherl, Ellen J., additional, Sandler, Robert, additional, Brotherton, Carol, additional, Albenberg, Lindsey, additional, Valentine, John F., additional, Suskind, David, additional, Meyer, Andrea, additional, Compher, Charlene W., additional, Bewtra, Meenakshi, additional, Kaur, Manreet, additional, Dassopoulos, Themistocles, additional, Snapper, Scott B., additional, Korzenik, Joshua R., additional, Bohm, Matthew, additional, Raffals, Laura, additional, Beniwal-Patel, Poonam, additional, Hudesman, David, additional, Russ, Kirk, additional, Brook, Loren, additional, Pekow, Joel, additional, Cross, Raymond, additional, Wong, Uni, additional, Bishu, Shrinivas, additional, Duerr, Richard, additional, Caldera, Freddy, additional, Scoville, Elizabeth, additional, Deepak, Parakkal, additional, and Ciorba, Matthew, additional

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Author

Danese, Silvio, primary, Panaccione, Remo, additional, Feagan, Brian G, additional, Afzali, Anita, additional, Rubin, David T, additional, Sands, Bruce E, additional, Reinisch, Walter, additional, Panés, Julián, additional, Sahoo, Aparna, additional, Terry, Natalie A, additional, Chan, Daphne, additional, Han, Chenglong, additional, Frustaci, Mary Ellen, additional, Yang, Zijiang, additional, Sandborn, William J, additional, Hisamatsu, Tadakazu, additional, Andrews, Jane M, additional, D'Haens, Geert R, additional, Oliinyk, Oleksandr, additional, Bilianskyi, Leonid, additional, Gniady-Jastrzebska, Jadwiga, additional, Petryka, Robert, additional, Arlukowicz, Tomasz, additional, Gietka, Piotr, additional, Zmudzinski, Marcin, additional, Mumtaz, Syed, additional, Wolf, Douglas, additional, Wojcik, Katarzyna, additional, Duvall, George, additional, Augustyn, Monika, additional, Filip, Rafal, additional, Tarabar, Dino, additional, Tkachev, Alexander, additional, Seidler, Ursula, additional, Zittan, Eran, additional, Pokrotnieks, Juris, additional, Shchukina, Oksana, additional, Machavariani, Andro, additional, Loy, Laura, additional, Abu-farsakh, Niazy, additional, Marina, Pesegova, additional, Sreckovic, Slobodan, additional, Laclav, Martin, additional, Wei, Shu-Chen, additional, Suiter, Daniel, additional, Borsuk, Aleksey, additional, Hebuterne, Xavier, additional, Buning, Carsten, additional, Lahat-Zok, Adi, additional, Danilkiewicz, Wit, additional, Frysna, Bernadetta, additional, Jovicic, Ivana, additional, Datsenko, Olena, additional, Guram, Maninder, additional, Jain, Animesh, additional, Rashid, Zahid, additional, Heeren, Sonja, additional, Shulga, Natallia, additional, Timkin, Ivan, additional, Gornjakovic, Srdjan, additional, Lukas, Milan, additional, Altwegg, Romain, additional, Desjeux, Ariadne, additional, Reimund, Jean-Marie, additional, Giorgadze, Manana, additional, Jochum, Christoph, additional, Ito, Hiroaki, additional, Nakai, Katsuhiko, additional, Takagi, Tomohisa, additional, Zaha, Osamu, additional, Choi, Changhwan, additional, Kim, Taeoh, additional, Lee, Jonghun, additional, Stundiene, Ieva, additional, Hilmi, Ida Normiha, additional, Hj Md Said, Rosaida, additional, Leszczyszyn, Jaroslaw, additional, Abdulganieva, Diana, additional, Fominykh, Yulia, additional, Maksyashina, Svetlana, additional, Balaz, Jozef, additional, Van Domselaar, Manuel, additional, Kav, Taylan, additional, Dennis, Patrick, additional, Henry, Patricia, additional, Holmes, Robert, additional, Johnson, Christopher, additional, McBride, Matthew, additional, Sarles, Harry, additional, Moore, Gregory, additional, Yakubtsevich, Ruslan, additional, Muls, Vinciane, additional, Trbojevic, Stevan, additional, Afif, Waqqas, additional, Bernstein, Charles, additional, Klarin, Ivo, additional, Serclova, Zuzana, additional, Volfova, Miroslava, additional, Desreumaux, Pierre, additional, Gilletta de Saint Joseph, Cyrielle, additional, Roblin, Xavier, additional, Vuitton, Lucine, additional, Chelidze, Kakhaber, additional, Kuehbacher, Tanja, additional, Koutroubakis, Ioannis, additional, Cicala, Michele, additional, Fries, Walter, additional, Gasbarrini, Antonio, additional, Aoyama, Nobuo, additional, Hayashi, Yoshito, additional, Hirai, Fumihito, additional, Horiki, Norkiyuki, additional, Hoshi, Namiko, additional, Inaba, Tomoki, additional, Hiroyasu, Ishida, additional, Maemoto, Atsuo, additional, Matsumoto, Takayuki, additional, Matsushima, Kayoko, additional, Motoya, Satoshi, additional, Taruishi, Masaki, additional, Rashid, Mohammed, additional, Chun, Jaeyoung, additional, Kim, Young-Ho, additional, Park, Dong Il, additional, Sharara, Ala, additional, Jonaitis, Laimas, additional, Deriban, Gjorgi, additional, Brooker, James, additional, Gawdis-Wojnarska, Beata, additional, Wozniak-Stolarska, Barbara, additional, Andreev, Pavel, additional, Simanenkov, Vladimir, additional, Trofimov, Vasiliy, additional, Jovanovic, Igor, additional, Zdravkovic, Natasa, additional, Aldeguer i Mante, Xavier, additional, Hernandez Ramirez, Vicent, additional, Akpinar, Hale, additional, Celebi, Gurkan, additional, Hamzaoglu, Hulya, additional, Fernandez, Juan, additional, Kamath, Jayaprakash, additional, Palekar, Nicole, additional, Pruthi, Jatinder S., additional, Rausher, David, additional, and Ritter, Timothy, additional

Published
2024
Full Text
View/download PDF

8. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.

Author

Danese, Silvio, Panaccione, Remo, Abreu, Maria T, Rubin, David T, Ghosh, Subrata, Dignass, Axel, Afzali, Anita, Wolf, Douglas C, Chiorean, Michael V, Vermeire, Severine, Jain, Anjali, Charles, Lorna, Lawlor, Garrett, Osterman, Mark T, Wu, Hsiuanlin, Canavan, James B, Petersen, AnnKatrin, Colombel, Jean-Frederic, and Regueiro, Miguel

Abstract

Backgrounds and Aims This interim analysis from the True North open-label extension [OLE] study examines efficacy and safety of approximately 3 years of continuous ozanimod treatment in patients with moderately to severely active ulcerative colitis. Methods Clinical responders after 52 weeks of ozanimod during the phase 3 True North study, who continued treatment in the OLE, were evaluated. Efficacy, including endoscopic and histological endpoints, was assessed during the OLE for approximately 2 additional years through OLE Week 94, using observed case [OC] and nonresponder imputation [NRI] analyses. Adverse events were monitored from True North baseline through OLE data cutoff and expressed as exposure-adjusted incidence rates. Results This analysis included 131 patients; 54% had achieved corticosteroid-free remission at True North Week 52. In OC analyses, clinical response, clinical remission, and corticosteroid-free remission were achieved by 91.4%, 69.1%, and 67.9% of patients, respectively, at OLE Week 94 [146 weeks of total treatment]. Similarly, endoscopic improvement, histological remission, and mucosal healing were achieved by 73.3%, 67.3%, and 56.3% of patients, respectively, at OLE Week 94. Efficacy rates were lower using NRI analyses, but maintenance of efficacy was demonstrated through OLE Week 94. No new safety signals emerged from this analysis. Serious infections, malignancy, cardiovascular events, and hepatic events occurred infrequently. Conclusions Among patients who achieved clinical response after 1 year of ozanimod treatment during True North, a high percentage sustained clinical and mucosal efficacy over 2 additional years in the OLE. No new safety signals were observed with long-term ozanimod use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES

Author

Panaccione, Remo, Danese, Silvio, Feagan, Brian G., D’Haens, Geert, Afzali, Anita, Reinisch, Walter, Panés, Julián, Rubin, David T., Andrews, Jane M., Hisamatsu, Tadakazu, Terry, Natalie A., Salese, Leonardo, Van Rampelbergh, Rian, Frustaci, Mary Ellen S., Yang, Zijiang, Johanns, Jewel, Wan, Kitty Y., Yee, Jacqueline, and Sands, Bruce E.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results